Progress in radiotherapy for early breast cancer

Annals of Oncology

Volumn 19, Issue SUPPL. 5, 2008, Pages

  Bartelink, H ^a  

^a ANTONI VAN LEEUWENHOEK HOSPITAL   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOPHOSPHAMIDE; DOXORUBICIN; FLUOROURACIL; METHOTREXATE; PACLITAXEL; TAMOXIFEN; TRASTUZUMAB;

AGE; BREAST CANCER; BREAST SURGERY; CANCER ADJUVANT THERAPY; CANCER CONTROL; CANCER PATIENT; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER SURVIVAL; CLINICAL TRIAL; CONFERENCE PAPER; EARLY CANCER; EXCISION; GENE EXPRESSION PROFILING; GENOMICS; HUMAN; MASTECTOMY; MULTIPLE CYCLE TREATMENT; PATIENT SELECTION; PRIORITY JOURNAL; PROGNOSIS; RADIATION DOSE; SEGMENTAL MASTECTOMY; SYSTEMIC THERAPY; ADJUVANT CHEMOTHERAPY; ADJUVANT THERAPY; ARTICLE; BREAST TUMOR; FEMALE; PATHOLOGY;

BREAST NEOPLASMS; CHEMOTHERAPY, ADJUVANT; FEMALE; HUMANS; NEOADJUVANT THERAPY; RADIOTHERAPY, ADJUVANT;

EID: 49049120771     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdn324     Document Type: Conference Paper

References (25)

1. Early Breast Cancer Trialists Collaborative Group (EBCTCG). Lancet 2005; 366: 2087-2106.
2. Kroman N, Holtveg H, Wohlfahrt J et al. Effect of breast-conserving therapy versus radical mastectomy on prognosis for young women with breast carcinoma. Cancer 2004; 100: 688-693.
3. Arriagada R, Le MG, Guinebretiere JM et al. Late local recurrences in a randomized trial comparing conservative treatment with total mastectomy in early breast cancer patients. Ann Oncol 2003; 14: 1617-1622.
4. Jobsen JJ, van der Palen J, Ong F, Meerwaldt JH. The value of a positive margin for invasive carcinoma in breast-conservative treatment in relation to local recurrence is limited to young women only. Int J Radiat Oncol Biol Phys 2003; 57: 724-731.
5. Vrieling C, Collette L, Fourquet A et al. EORTC Radiotherapy, Breast Cancer Groups. Can patient-, treatment- and pathology-related characteristics explain the high local recurrence rate following breast-conserving therapy in young patients? Eur J Cancer 2003; 39: 932-944.
6. Bartelink H, Horiot JC, Poortmans P et al. Recurrence rates after treatment of breast cancer with standard radiotherapy with or without additional radiation. N Eng J Med 2001; 345: 1378-1387.
7. Bartelink H, Horiot JC, Poortmans PM et al. Impact of a higher radiation dose on local control and survival in breast-conserving therapy of early breast cancer: 10-year results of the randomized boost versus no boost EORTC 22881-10882 trial. J Clin Oncol 2007; 25: 3259-3265.
8. Bartelink H, Rubens RD, van der Schueren E, Sylvester R. Hormonal therapy prolongs survival in irradiated locally advanced breast cancer: a European Organization for Research and Treatment of Cancer randomized phase III trial. J Clin Oncol 1997; 15: 207-215.
9. Livi L, Paiar F, Saieva C et al. Survival and breast relapse in 3834 patients with T1-T2 breast cancer after conserving surgery and adjuvant treatment. Radiother Oncol 2007; 82: 287-293.
10. Antonini N, Jones H, Horiot JC et al. Effect of age and radiation dose on local control after breast conserving treatment: EORTC trial 22881-10882. Radiother Oncol 2007; 82: 265-271.
11. Forrest AP, Stewart HJ, Everington D et al. Randomised controlled trial of conservation therapy for breast cancer: 6-year analysis of the Scottish trial. Scottish Cancer Trials Breast Group. Lancet 1996; 348: 708-713.
12. Fisher B, Bryant J, Dignam JJ et al. Tamoxifen, radiation therapy, or both for prevention of ipsilateral breast tumor recurrence after lumpectomy in women with invasive breast cancers of one centimeter or less. J Clin Oncol 2002; 20: 4141-4149.
13. Hughes presentation at SABCS. 2006.
14. Fyles presentation at ASTRO. 2006.
15. van de Vijver MJ, He YD, van't Veer LJ et al. A gene-expression signature as a predictor of survival in breast cancer. N Engl J Med 2002; 347: 1999-2009.
16. Recht A, Come SE, Henderson IC et al. The sequencing of chemotherapy and radiation therapy after conservative surgery for early-stage breast cancer. N Engl J Med 1996; 334: 1356-1361.
17. Bellon JR, Come SE, Gelman RS et al. Sequencing of chemotherapy and radiation therapy in early-stage breast cancer: Updated results of a retrospective randomized trial. J Clin Oncol 2005; 23: 1934n.
18. Huang J, Barbera L, Brouwers M et al. Does delay in starting treatment affect the outcomes of radiotherapy? A systematic review. J Clin Oncol 2003; 21: 555-563.
19. Mauri D, Pavlidis N, Ioannidis JP. Neoadjuvant versus adjuvant systemic treatment in breast cancer: A meta-analysis. J Natl Cancer Inst 2005; 97: 188-194.
20. Chien KR. Focus on research: Herceptin and the heart - a molecular modifier of cardiac failure. N Engl J Med 2006; 354: 789-790.
21. Halyard MY, Pisansky TM, Solin LJ et al. Adjuvant radiotherapy and trastuzumab in stage I-IIA breast cancer: Toxicity data from North Central Cancer Treatment Group Phase III trial N9831. Proc Am Soc Clin Oncol 2006; 24: 8S (Abstr 523).
22. Gagliardi G, Lax I, Rutqvist LE. Partial irradiation of the heart. Semin Radiat Oncol 2001; 11: 224-233.
23. Hooning MJ, Botma A, Aleman BM et al. Long-term risk of cardiovascular disease in 10-year survivors of breast cancer. J Natl Cancer Inst 2007; 99: 365-375.
24. Polgár C, Fodor J, Major T et al. Breast-conserving treatment with partial or whole breast irradiation for low-risk invasive breast carcinoma-5-year results of a randomized trial. Int J Radiat Oncol Biol Phys 2007; 69: 694-702.
25. Nuyten DSA, Kreike B, Hart AAM et al. Predicting a local recurrence after breast-conserving therapy by gene expression profiling. Breast Cancer Res 2006; 8: R62.